ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2026
Clinical stage-dependent expression of MRE11 and its association with laryngeal cancer progression.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiotherapy is a mainstay of treatment for laryngeal cancer. MRE11, a core component of the MRN complex, contributes to radioresistance and also has a signalling function. This study examines the association between MRE11 expression and tumour progression in patients with laryngeal cancer treated at Bulovka University Hospital in Prague. Materials and methods: This retrospective study included 108 patients with laryngeal cancer treated with radiotherapy. Immunohistochemical analysis was performed on pretreatment biopsy samples to evaluate the expression of selected DNA repair proteins and statistically assess their impact on treatment outcomes. Results: Of the proteins studied, MRE11 showed the strongest statistical association, with significantly higher expression in early clinical stages I-II and lower expression in stages III-IV (p < 0.001). Higher MRE11 expression was associated with better overall survival (p < 0.001) and longer progression-free survival (p = 0.025). No significant relationship was observed between analysed protein expression and treatment toxicity. Conclusions: In our cohort of patients with laryngeal carcinoma treated with radiotherapy, elevated immunohistochemical expression of MRE11 was associated with less advanced disease and improved treatment outcomes, in contrast to findings in other head and neck cancers. This discrepancy may reflect the context-dependent function of MRE11. Further research is needed to clarify the prognostic role of MRE11 and its potential use in guiding personalised treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.